Open in interactive viewer → charts, metric popovers & call review

Agfa's €1 Million Quarter Comes Wrapped in Silver Foil

HealthCare IT cloud orders more than tripled and recurring revenue hit a record — yet a silver-price accounting cycle and a lengthening cloud J-curve dragged group EBITDA to €1 million and pushed the margin pivot out to 2028.
AGFB.BR · Earnings Call · 2026-11-10

A quarter you are explicitly told not to look at

Agfa-Gevaert is now, post-carve-out, a two-headed company: HealthCare IT, and an Advanced Materials-heavy industrial rump that management has rebranded Imaging & Advanced Materials. The headline was flat — €210 million of revenue against €210 million — but the second line was not: adjusted EBITDA of €1 million versus €4 million a year earlier. “Q3 is typically a rather weak quarter, and this one was no exception.” — Pascal Juery, CEO · 2026-11-10 The two halves are moving in opposite directions. HealthCare IT sales rose 11% with a better EBITDA contribution; Imaging & Advanced Materials fell and swung negative, and the CEO conceded that Digital Radiology's year-long go-to-market rebuild and a near-blank year in green hydrogen more than offset improved Film & Chemicals. On a nine-month view the picture softens — €631 million of sales against €647 million, but EBITDA of €25 million against €22 million. That gap between the quarter and the year-to-date is the whole argument management is making, and this quarter it needed help making it.

Silver is doing the talking

The genuinely new thing on this call is not a strategy; it is a commodity accounting cycle. Silver has always been a footnote at Agfa, but this quarter it became the loudest voice in the P&L, and the keyword set reflects that shift: silver volatility is now the company's leading narrative theme, with ~physical hedging and a new vocabulary around the cash cycle following it up the rankings. The mechanics, as laid out by new CFO Declan Guerin: silver is bought upfront for cash, held in inventory and revalued to market, sold through film with a pricing lag of roughly a quarter, and only collected months later. Silver started the year near $88 an ounce and sits around $62 today, so the timing effects ran hard in both directions. The nine-month tally: sales impact of plus €45 million, a plus €5 million gross-margin impact, and a cash hit of just over €30 million.

We can and do pass on the impact of the change in prices to our customers. But over the cycle, it's neutral... But in the short term, it does create a ripple effect in our numbers, especially if silver prices move around.

Michael Guerin, CFO · 2026-11-10
That is honest, and it is also convenient: it means the reported EBITDA is a poor read on operating reality, and an analyst trying to model the industrial segment has to strip out a commodity timing item with a cash tail running into 2027. Note the segment's year-to-date gross margin is 20.6% against 20.7%, and year-to-date segment EBITDA actually improved to €21 million from €15 million — the quarterly collapse is largely the reversal of a first-quarter gain. The remedies on offer (leaner inventory, steadier purchase cadence, indexation, possibly vendor financing) are sensible, but they are process fixes, not a fix for the underlying economics.

The cloud J-curve just got longer

HealthCare IT is the part of this company that works. Twelve-month rolling order intake rose 21% to €197 million, roughly double the level of five years ago; cloud order intake reached €91 million, more than tripling, and now approaches half of total intake — overwhelmingly from new logos rather than the installed base. Recurring revenue hit 69% of quarterly sales, the highest ever, versus barely above 50% a few years back. And yet guidance went down. Profitability for 2026 will be slightly below last year, and the reason given is that the cloud transition is happening faster than planned — a genuine J curve that the company had previously been flattening into an "L". The pivot year is now explicitly 2028; 2027 will look like 2026. “We have the potential to reach in this business, I would say, approximately more than 20% over time.” — Pascal Juery, CEO · 2026-11-10 Here is the tension worth flagging. The framework itself is not new. Eighteen months ago the CEO set out the identical mechanics:

Typically, what you see in a business making a SaaS transition is a sales dip and a profit dip for two, three years.

Pascal Juery, Chief Executive Officer (CEO) · 2025-03-12
That framing implied an inflection around 2027. It has now been superseded by 2028, and last quarter an analyst asked the same accretive-margin question; the answer then was that cloud acceleration was suppressing reported profit. So the question is not new — the answer's date keeps sliding. That is the difference between a transition and a treadmill, and it is the single most important thing to monitor here. There is also a quieter relocation of the strategic-optionality debate. Last quarter, an analyst asked whether the new CFO's carve-out pedigree pointed toward a separation of HealthCare IT. “I'm not going to comment on that. Clearly, the first priority we have for HealthCare IT today is to succeed the cloud transition.” — Pascal Juery, CEO · 2026-08-26 This quarter, the same analyst aimed "strategic alternatives" at the underperforming industrial assets instead, and the CEO defended the film restructuring as already radical — production headcount nearly halved. The question has migrated from the crown jewel to the laggard. That usually means someone has stopped arguing.

Cash, carve-outs and a new voice on the line

Guerin's debut was disarmingly candid — “very glad to be here on my first quarterly call. So do give me a little bit of latitude” — Michael Guerin, CFO · 2026-11-10 — and the numbers he presented were fine on the covenant side but ugly on the cash side. Q3 free cash flow was minus €14 million, driven by transformation payouts; adjusted free cash flow was plus €8 million. Leverage sits at 1.9x against a 3.0x covenant maximum, interest cover at 8.6x against a 4.0x floor, liquidity just under €96 million against a €30 million minimum, and the revolver was extended to August 2030. Roughly half of the restructuring provisions have been consumed in cash; €64 million of savings are banked. The framing, though, has shifted from self-funding to survival financing. Last quarter: “today we have a recurring level of savings of more than EUR 60 million” — Pascal Juery, CEO · 2026-08-26 covering implementation cost. This quarter, with a saving plan already delivered: “I still see the next couple of years to be transformation years where we will have to spend still a significant amount in restructuring” — Pascal Juery, CEO · 2026-11-10 — with pensions, per the CEO, "not going away." Digital Printing Solutions, now discontinued and due to combine with EFI by year-end, is the offsetting good news: sales down 10% on equipment timing, but ink volumes up 12% and EBITDA up year-on-year, with Q4 visibility on firm orders. The CEO's closing plea — “don't look at the quarter. You need to look on a larger period” — Pascal Juery, CEO · 2026-11-10 — is the right instruction and also the standard one. Which brings us to the oldest deferred story in this file: Green hydrogen, a fixture of Agfa's narrative since 2022, has been "almost a missed year" in 2026 with the rebound promised for 2027. A year ago the same executive said only that “we have visibility on ZIRFON, but not yet for the 2026” — Pascal Juéry, Chief Executive Officer · 2025-05-14. The year rolls; the visibility always sits twelve months out. At a market capitalisation under €64 million with no usable price tape, there is no investor vote to read — only the cash flow statement. On that measure, Agfa is a company whose best asset (cloud radiology) is diluting reported profit exactly as its worst asset (silver-heavy film) distorts it, and whose pivot keeps being promised for the year after next.